Summary of the FDA virtual public workshop on spinal device clinical review held on September 17, 2021

Vincent J. Devlin, Ronald Jean, CAPT Raquel Peat, Hongying Jiang, Paul A. Anderson, John C. Benson, Darrel S. Brodke, S. Raymond Golish, Khaled M. Kebaish, A. Noelle Larson, Hassan Serhan

Research output: Contribution to journalReview articlepeer-review

Abstract

The mission of Food and Drug Administration (FDA)’s Center for Devices and Radiological Health is to protect and promote public health. It assures that patients and providers have timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products by providing meaningful and timely information about the products we regulate and the decisions we make. On September 17, 2021, an FDA workshop was held to provide information to stakeholders, including members of the spine community, device manufacturers, regulatory affairs professionals, clinicians, patients, and the general public regarding FDA regulations, guidance and regulatory pathways related to spinal device clinical review. It was not intended to communicate any new policies, processes, or interpretations regarding medical device marketing authorizations. This workshop consisted of individual presentations, group discussions, question and answer sessions, and audience surveys. Information-sharing included discussions related to patient-reported outcomes, clinician-reported outcomes, observer-reported outcomes, and performance outcomes. Discussions involving external subject matter experts covered topics related to spinal device clinical studies including definition of a target population, enrollment criteria, strategies for inclusion of under-represented patient groups, reporting of adverse event and secondary surgical procedures, clinical study endpoints, and clinical outcome assessments. A meeting transcript and webcast workshop link are currently posted on the FDA website. Important related issues and challenges were discussed, and an exciting range of new ideas and concepts were shared which hold promise to advance regulatory science, patient care and future innovation related to spinal devices.

Original languageEnglish (US)
Pages (from-to)1423-1433
Number of pages11
JournalSpine Journal
Volume22
Issue number9
DOIs
StatePublished - Sep 2022

Keywords

  • Adverse events
  • Clinical outcome assessments
  • Clinical study endpoints
  • De Novo Classification request
  • Health disparities
  • Humanitarian device exemption
  • Investigational device exemption
  • Orthopedic devices
  • Premarket approval
  • Premarket notification
  • Secondary surgical procedures
  • Spinal devices
  • Spinal fusion
  • Study enrollment criteria

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Orthopedics and Sports Medicine

Fingerprint

Dive into the research topics of 'Summary of the FDA virtual public workshop on spinal device clinical review held on September 17, 2021'. Together they form a unique fingerprint.

Cite this